GlassScriptPhysician profile
Marta A Recasens
NPI 1467541508
$2,720.43
in general payments reported to CMS, 2019-2025
21 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $382 · 2021: $181 · 2022: $469 · 2023: $167 · 2024: $389 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $430.03 | 2019-2023 | |
| Astellas Pharma US INC | $416.72 | 2024-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $304.85 | 2019-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $275.91 | 2019-2020 | |
| Alcon Vision LLC | $204.87 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Sun Pharmaceutical Industries INC. | $179.61 | 2020-2022 | |
| Notal Vision, INC. | $157.27 | 2022 | |
| Apellis Pharmaceuticals, INC. | $146.70 | 2023-2025 | Syfovre |
| Eyevance Pharmaceuticals LLC | $101.33 | 2020-2023 | Flarex |
| Glaukos Corporation | $77.14 | 2020 | |
| Oyster Point Pharma, INC. | $73.70 | 2022-2023 | Tyrvaya |
| Alimera Sciences, INC. | $60.24 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $58.81 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.59 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $45.55 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $30.13 | 2019 | |
| Katena Products, INC. (Dba Corza Medical) | $28.54 | 2019 | |
| Kala Pharmaceuticals, INC. | $23.33 | 2019 | |
| Shire North American Group INC | $20.75 | 2019 | |
| Bausch & Lomb Americas INC. | $18.23 | 2025 | Vyzulta |
| Biogen, INC. | $18.13 | 2024 | Byooviz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Recasens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.